P2901 - Trends of Cirrhosis in Patients With Sickle Cell Disease - Analysis Using National Inpatient Sample

Manasa Ginjupalli, MBBS, MD¹, Jayalekshmi Jayakumar, MBBS, MD², Gloria Basil, MBBS³, Anuj R. Sharma, MBBS⁴, Hima Varsha. Voruganti, MBBS, MD⁵, Vikash Kumar, MD⁶, Arnold N. Forlemu, MD, MPH^7
1The Brooklyn Hospital Center, New York, NY; ²The Brooklyn Hospital Center, Brooklyn, NY; ³St. George's University School of Medicine, Brooklyn, NY; ⁴Brooklyn Hospital Center, Brooklyn, NY; ⁵North Alabama Medical Center, Florence, AL; ⁶Creighton University School of Medicine, Brooklyn, NY; ⁷Brooklyn Hospital Center, Athens, GA

Introduction: Sickle cell disease [SCD], an inherited blood disorder, and liver cirrhosis, a progressive liver condition characterized by scarring, both present significant health effects. Traditionally there is a heightened burden of chronic liver complications in individuals with SCD, likely attributed to intrahepatic sickling of erythrocytes, increased chance of viral hepatitis and iron overload resulting from multiple blood transfusions. In this study, we tried to analyze the trends of cirrhosis hospitalizations among patients with and without SCD across the United States.

Methods: A retrospective analysis was performed on the National Inpatient Sample database 2016- 2020 and ICD-10 codes were used to identify hospitalized adults with diagnosis of cirrhosis and stratified for the presence of SCD. Trends of mortality and morbidity outcomes of cirrhosis in hospitalized patients with and without SCD were analyzed. Categorical variables were compared using chi square and continuous variables were compared using t test. Multivariate regression analysis was performed adjusting for demographics, patient and hospital-level characteristics, and relevant comorbidities.

Results: A total of 3,738,364 hospitalized adults with cirrhosis were identified of which 0.19% had SCD (n=467080). Mean age of hospitalized adults with SCD is 47.05 years and without SCD was 60.40 years, of which 54.9% and 40.4% were females, with without SCD respectively. Hospitalizations of cirrhosis patients with SCD demonstrated an increase in the United States from 1365 (1.42% of the total admissions) in 2016 to 1595 (1.87% of the total admissions) in 2020. The trend among cirrhosis patients without SCD was similar with 682,934 (2.27% of the total admissions) in 2016 to 782,764 (2.85% of the total admissions) in 2020. Trends of mortality and morbidity outcomes of cirrhosis with and without SCD were analyzed and reported. [Table1, Image1]. Multivariate regression analysis revealed a significant variation in trends for mortality, however trends were not statistically significant among complications [Table 1]

Discussion: Over the years, mortality rates among cirrhosis hospitalizations in patients with SCD have shown a declining trend. On the contrary, the trends of mortality have been relatively stable among patients without SCD. Similarly, a decline in complications is observed in populations without SCD. This trend may be partially attributed to improved healthcare utilization and the availability of multidisciplinary care in management.



Disclosures:


Manasa Ginjupalli, MBBS, MD¹, Jayalekshmi Jayakumar, MBBS, MD², Gloria Basil, MBBS³, Anuj R. Sharma, MBBS⁴, Hima Varsha. Voruganti, MBBS, MD⁵, Vikash Kumar, MD⁶, Arnold N. Forlemu, MD, MPH⁷. P2901 - Trends of Cirrhosis in Patients With Sickle Cell Disease - Analysis Using National Inpatient Sample, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.